Float & OS3.87 M / 5.49 M
Cash/Shr$0.40
Market Cap & EV—
Short Interest—
Cash$2.19 M
Est. Cash Today$-727,493.86
Off AbilityMedium
Off FreqMedium
DilutionHigh
Cash NeedHigh
Overall Offering RiskHigh
Warrant Exercise RiskHigh
Nasdaq ComplianceLow
Shares Outstanding History
Cash Position
Cash Position
The company has -0.7 months of cash left based on the quarterly cash burn of $-2.96 M and estimated current cash of $-727,493.86.
Commentary on Financial Condition
“from BayMedica product sales and no sales from any other sources and have incurred significant operating losses and negative cash flows from our operation. We have not yet commercialized any of our Product Candidates and we do not expect to generate revenue from sales of” (from May 2026 filing’s Liquidity and Capital Resources) Filed At: 2026-05-06
Recent Filings
| 4 | Form 4 | 2026-10-09 |
| SCHEDULE 13G/A | Form SCHEDULE 13G/A | 2026-10-08 |
| 4 | Form 4 | 2026-10-06 |
| EFFECT | Form EFFECT | 2026-10-02 |
| 424B3 | Form 424B3 | 2026-10-02 |
| S-4/A | Form S-4/A | 2026-09-30 |
| 8-K | Form 8-K | 2026-09-19 |
| 4 | Form 4 | 2026-09-17 |
Insights
The company received a deficiency notice from Nasdaq for minimum bid price on June 10, 2026.
· 2026-06-10
The company completed 1 offering(s) in the last twelve months, raising $1,119,279.
· 2026-04-03
An at-the-market programme of up to $1,119,279 is in place with Wainwright.
424B5 · 2026-04-03
A shelf registration of $50,000,000 is on file, of which $1,119,279 has been taken down, leaving $48,880,721 available.
S-3 · 2026-03-31
The company received a deficiency notice from Nasdaq for minimum bid price on March 30, 2026.
· 2026-03-30